Drug Profile
Peginterferon beta-1a - Biogen
Alternative Names: BIIB 017; PEG-interferon-β-1a; PEGylated INF-beta-1a - Biogen; PlegridyLatest Information Update: 14 Dec 2022
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class Interferons
- Mechanism of Action Immunomodulators; Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
Most Recent Events
- 21 Jul 2022 Biogen terminates a phase III in Multiple sclerosis (In children's, In adolescents, Combination therapy) in Colombia, Jordan, South Korea, Malaysia, Mexico, Saudi Arabia, Taiwan, Thailand, Tunisia, Turkey, Estonia, Hungary and USA (SC, Injection) due to long-term difficulties faced in fulfilling enrolment commitments(NCT03870763)
- 02 Apr 2022 Adverse events and pharmacokinetics data from a phase I trial in Multiple-sclerosis presented at the 74th Annual Meeting of the American Academy of Neurology 2022(AAN-2022)
- 02 Apr 2022 Biogen completes phase I pharmacokinetics trial for Multiple sclerosis (In volunteers) in the USA prior to April 2022